Certara, Inc. (NASDAQ: CERT) reported Q4 EPS of $0.09, $0.06 better than the analyst estimate of $0.03. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $60.97 million.

“Certara had another year of strong financial performance in 2020 with continued robust adoption of our end-to-end platform. Our dedicated Certara team achieved record full year revenue despite the challenges of the COVID-19 pandemic, delivering 17% growth in revenue and 18% growth in operating cash flow,” said William F. Feehery, chief executive officer. “We successfully completed our IPO in December and are now better positioned to execute on our mission to accelerate the drug development process using our biosimulation software and technology-enabled services.”

GUIDANCE:

Certara, Inc. sees FY2021 revenue of $272-285 million, versus the consensus of $269.39 million.

For earnings history and earnings-related data on Certara, Inc. (CERT) click here.